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Abstract
Background: Emergence of daptomycin-nonsusceptible (DNS) Staphylococcus aureus is a dreadful problem in the
treatment of endocarditis. Few current therapeutic agents are effective for treating infections caused by DNS S.
aureus.
Case presentation: We describe the emergence of DNS S. aureus. in a patient with implantable cardioverter-
defibrillator (ICD) device -related endocarditis who was priorily treated with daptomycin. Metastatic dissemination
as osteomyelitis further complicated the management of endocarditis. The dilemma was successfully managed by
surgical removal of the ICD device and combination antimicrobial therapy with high-dose daptomycin and
fosfomycin.
Conclusions: Surgical removal of intracardiac devices remains an important adjunctive measure in the treatment
of endocarditis. Our case suggests that combination therapy is more favorable than single-agent therapy for
infections caused by DNS S. aureus.
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Background
Infective endocarditis is a clinically significant disease
with mortality ranging from 16% to 25% [1,2], and Sta-
phylococcus aureus is reported as the most common
pathogen, accounting for 31.4% of cases in developing
countries [3]. In addition to methicillin-resistant S. aur-
eus (MRSA), the emergence of vancomycin-resistant S.
aureus also became a major problem after the first
report in Japan in 1997 [4].
Daptomycin is a 13-aminoacid compound derived
from fermentation of Streptomyces roseosporus and is a
new treatment option for S. aureus endocarditis, includ-
ing vancomycin-resistant S. aureus [5,6]. The once daily
dosing of daptomycin 6 mg/kg approved by the USA
Food and Drug administration showed non-inferiority to
the standard therapy for treating S. aureus bacteremia
and endocarditis [7]. However, increased incidence of
daptomycin-nonsusceptible (DNS) S. aureus was
reported recently. Mutations in the mprF and yycFG
genes, related to membrane fluidity changes or fatty
acid biosynthesis, were identified recently as possible
contributors to daptomycin nonsusceptibility [5,8].
Effective management in case of DNS S. aureus infec-
tions is an important issue nowadays.
Fosfomycin, a phosphonic acid derivative (cis-1,2-
epoxypropyl phosphonic acid), was initially described
and isolated in 1969 from cultures of Streptomyces spe-
cies [9]. It was commonly employed in treating urinary
tract infections and has a bactericidal mechanism of
action [9,10]. Because it is a relatively small, hydrophilic
molecule with almost negligible serum protein binding
and good tissue penetration, this agent was more
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frequently used in combination therapy for treating mul-
tidrug-resistant pathogens [10,11].
We present our treatment experience utilizing surgical
intervention and high-dose daptomycin in combination
with fosfomycin for successful treatment of a patient
with implantable cardioverter-defibrillator (ICD) device-
related endocarditis complicated with osteomyelitis
caused by DNS MRSA.
Case Presentation
A 28-year-old woman had a history of sudden onset of
syncope diagnosed as paroxysmal ventricular tachycar-
dia. She underwent electric ablation and placement of
an ICD in her left shoulder. She had poor wound heal-
ing at a 5-month follow-up visit and she was admitted
to the hospital on December 1, 2008 for management of
a pocket infection. Exposure of the ICD generator and
pacing lead were found on February 26, 2009, and the
generator was removed, leaving the pacing lead in place.
She had episodic pyrexia beginning in May 2009 and
her blood cultures grew MRSA (isolate st01, positive in
one of two sets blood cultures collected). ICD device-
related endocarditis was highly suspected. Intravenous
antibiotics with vancomycin 1 g every 12 hours for 14
days followed by oral linezolid 600 mg every 12 hours
for another 14 days were prescribed for her endocarditis,
but the blood cultures still grew MRSA (isolate st02,
positive in one of two sets blood cultures collected). A
thoracotomy was planned to remove the pacing lead.
However, because of three episodes of broken peripheral
venous catheter tips left in the vessels, generator displa-
cement requiring surgical intervention, and emotional
fragility, the surgical intervention was postponed due to
the high possibility of postoperative wound infection
and further osteomyelitis. Daptomycin at a dosage of 6
mg/kg daily was prescribed for its effective biofilm pene-
tration ability and rapid bacteriocidal efficacy, and the
subsequent blood culture (one set collected) yielded
negative finding. A total 65 days of treatment were com-
pleted and the patient was discharged on October 24,
2009.
Unfortunately, spiking fever and chills occurred 1 day
after discharge and the blood cultures grew MRSA again
(isolates st03, positive in one of two blood cultures col-
lected). During antibiotic treatment with intravenous
tigecycline (100-mg loading dose and 50 mg every 12
hours for 14 days), one of two sets of blood cultures
grew MRSA (isolate st04). Teicoplanin 400 mg every 12
hours for another 14 days was given, but another one of
two sets of blood cultures grew MRSA (isolate st05).
Intravenous daptomycin was prescribed at a dosage of
up to 9 mg/kg daily in combination with intravenous
fosfomycin 6 g every 6 hours starting December 16,
2009, due to the persistence of MRSA bacteremia with
the ICD device in place. The patient’s fever subsided
after these treatments and the next three sets of blood
cultures were negative 1 week after the start of dapto-
mycin-fosfomycin combination therapy. However, trans-
esophageal echocardiography revealed vegetations
growing on the pacing lead, and a scan for osteomyelitis
showed increased uptake of the radiotracer in the left
proximal clavicle. Moreover, the daptomycin Etest (AB
Biodisk, Solna, Sweden) of MRSA isolate st05 indicated
that it was nonsusceptible to daptomycin, with a mini-
mal inhibitory concentration (MIC) ranging from 1.5 to
2 mg/L. After discussion among the surgeons and infec-
tious disease specialists, a thoracotomy was performed
on December 22, 2009 for removal of the pacing lead
due to the previous persistence of S. aureus bacteremia;
high-dose daptomycin 12 mg/kg intravenously daily was
also started. A vegetation measuring 1.3 × 0.6 × 0.1 cm
was found on the pacing lead, but the Gram stain
showed no microbes. Tissue culture of the vegetation
found on the pacing lead grew MRSA (isolate st06), as
did as the tip of the pacing lead (isolate st07).
Because the osteomyelitis scan was positive, combina-
tion therapy with daptomycin 12 mg/kg intravenously
daily and fosfomycin 6 g intravenously every 6 hours
was administered for total of 56 days. The patient had
no further pyretic episodes following hospitalization. A
follow-up osteomyelitis scan on March 8, 2010 was
negative, and follow-up transthoracic echocardiography
showed no vegetation. The patient’s symptoms were
attributed to endocarditis; she remained symptom free
during 12 months of follow-up.
Methods
The species identification was completed using the API
32GN biochemical testing system (bioMérieux, Inc.,
Marcy l’Étoile, France). Antimicrobial susceptibility test-
ing was performed using agar dilution method with 25
mg/L glucose-6 phosphate added for fosfomycin testing;
the broth dilution method of antimicrobial susceptibility
testing was used for the other antimicrobial agents, as
specified by the Clinical Laboratory Standards Institute
(CLSI 2010), using the VITEK® 2 Compact system (bio-
Mérieux, Inc.,) and daptomycin Etest strips (AB Biodisk,
Solna, Sweden). Guidance for interpreting the MICs as
clinical categories (susceptible, intermediate, or resis-
tant) was provided by the manufacturer’s instructions
and CLSI criteria. Isolates with daptomycin MICs ≤ 1
mg/L were defined as daptomycin-susceptible, and those
with MICs > 1 mg/L were defined as daptomycin-non-
susceptible. No MIC interpretation criteria were avail-
able for fosfomycin on bacteremia in CLSI criteria, but
isolates with MICs less than 32 mg/L were defined as
susceptible by the European Committee on Antimicro-
bial Susceptibility Testing (EUCAST). In order to
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establish the clonality of these isolates, we performed
pulsed-field gel electrophoresis (PFGE) as described pre-
viously [12]. S. aureus ATCC 29213 was used as the
quality control organism.
Results
The seven isolates were analyzed by their Sma1 PFGE
profiles and isolates st02 to st06 showed the same pro-
file, while isolates st01 and st07 were different. Progres-
sive elevation of the daptomycin MICs for isolates of
the same clonality occurred, but decreasing MICs for
isolate st06 were noted for vancomycin, teicoplanin, and
daptomycin compared to those of isolate st05 (Table 1).
The MICs of fosfomycin for all isolates were less than 2
mg/L by the agar dilution methods and showed suscept-
ibility based on the EUCAST criteria. All isolates were
resistant to the other antimicrobials screened using the
VITEK® 2 Compact system (Table 1).
Conclusions
Combination therapy consisting of high-dose daptomy-
cin and fosfomycin is an alternative treatment option
for DNS MRSA native valve endocarditis or osteomyeli-
tis. These two agents are well known for their bacterio-
cidal activities and effective biofilm penetration
[5,6,10,11]. Recently, positive results for fosfomycin used
in combination with other antimicrobial agents against
multidrug resistant Gram-positive pathogens were also
reported [9,11].
Isolate st06 from the vegetation, of the same clonality as
isolate st05, was susceptible to vancomycin, teicoplanin,
and daptomycin in combination with fosfomycin with
additive effect. Additionally, the pathological findings of
the vegetation were negative for microbes, which sug-
gested that the combination regimen was highly effective
in biofilm penetration and killing the bacteria. Moreover,
the osteomyelitis was successfully treated in 8 weeks, with-
out complications. Although high-dose daptomycin treat-
ment could be effective after surgical removal of an ICD-
device for adequate pharmacodynamics attainments, the
combination therapy is preferred in complicated cases,
and further study to establish the adequate combination
dosage of daptomycin with fosfomycin is needed. Steed et
al. also reported that the combination of daptomycin plus
clotrimoxazole was bactericidal against DNS MRSA in an
in vitro model of simulated endocardial vegetations [13].
High-dose daptomycin treatment (12 mg/kg daily) was
well tolerated in our patient throughout the 8-week
treatment course. In a previous study, patients received
daptomycin in dosages greater than 8 mg/kg per day,
and 79% of patients were considered evaluable for effi-
cacy; only 6.4% experienced 1 or more adverse events or
abnormal laboratory analyte values [14]. Another recent
report also revealed no remarkable creatinine kinase ele-
vation after daptomycin use in dosage greater than 8
mg/kg once daily for a prolonged course of 14 days
[15]. Because the resistance mechanism of S. aureus to
daptomycin is unique in comparison to other glycopep-
tides, and every single gene mutation, such as mprF and
yycFG genes, causes only a slight increase in daptomycin
MIC, higher doses of daptomycin could still be effective
for the treatment of DNS S. aureus [5,8]. Nonetheless,
in vitro and in vivo evidence suggests that combination
therapy is more favorable than single-agent therapy for
infections caused by DNS S. aureus, and antibiotic ther-
apy must be individualized for each patient’s condition.
For patients with ICD device-related endocarditis, sur-
gical removal of the device is strongly recommended
when S. aureus bacteremia persists after antimicrobial
therapy [16,17]. As reported by del Rio A et al. the pre-
valence of treatment failure is greater among patients
receiving only antibiotics therapy compared to those
treated with surgical removal of implanted device and
antibiotics therapy [18]. Recurrence of MRSA bactere-
mia identified during our patient’s second visit suggested
treatment failure, even though the blood cultures were
negative after the initial daptomycin treatment; such
patients should undergo prompt surgical removal of the
ICD device. It is possible that with daptomycin alone
the patient could have been cured in the first attempt if
Table 1 Antimicrobial susceptibility results for the seven methicillin-resistant Staphylococcus aureus clinical isolates
Isolate Date of isolation MIC (mg/L)
Vitek 2 Broth dilution Agar dilution Etest
VAN TEIC LIN VAN TEIC DPC FOS DPC
st01 2009/5/19 < 0.5 < 0.5 2 1 1 0.25 < 2 0.19
st02 2009/9/27 2 < 0.5 2 1 1 0.25 < 2 0.38
st03 2009/10/29 2 < 0.5 4 1 1 0.5 < 2 0.25
st04 2009/11/10 1 < 0.5 4 1 1 0.5 < 2 0.25
st05 2009/12/11 2 2 4 2 0.25 1 < 2 1.5-2
st06 2009/12/22 2 < 0.5 2 1 0.5 0.5 < 2 0.25
st07 2009/12/22 2 1 4 2 4 2 < 2 1
DPC: daptomycin; FOS: fosfomycin; LIN: linezolid; MIC: minimal inhibitory concentration; TEIC: teicoplanin; VAN: vancomycin
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the ICD lead had been surgical removed. Although the
combination therapy achieved negative blood cultures,
the tissue culture of the vegetation and pacing lead still
grew MRSA, with isolate st07 showing increased dapto-
mycin resistance. Recurrence would have remained pos-
sible without the removal of the pacing lead.
Consent
Written informed consent was obtained from the patient
for publication of this case report.
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